Schonfeld Strategic Advisors LLC Keros Therapeutics, Inc. Transaction History

Schonfeld Strategic Advisors LLC

$14 Billion
Q1 2024

A detailed history of Schonfeld Strategic Advisors LLC transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 60,405 shares of KROS stock, worth $2.76 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

60,405

Previous 95,338 36.64%

Holding current value

$2.76 Million

Previous $3.79 Million 5.49%

% of portfolio

0.03%

Previous 0.03%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$41.26 - $70.48 $1.44 Million - $2.46 Million	-34,933 Reduced 36.64%	60,405 $4 Million
Q4 2023 Feb 14, 2024	BUY	$27.12 - $41.05 $475,630 - $719,934	17,538 Added 22.54%	95,338 $3.79 Million
Q3 2023 Nov 14, 2023	SELL	$31.57 - $43.02 $281,825 - $384,039	-8,927 Reduced 10.29%	77,800 $2.48 Million
Q2 2023 Aug 14, 2023	BUY	$37.26 - $51.01 $1.12 Million - $1.54 Million	30,182 Added 53.38%	86,727 $3.48 Million
Q1 2023 May 15, 2023	BUY	$41.44 - $59.32 $673,192 - $963,653	16,245 Added 40.31%	56,545 $2.41 Million

Q4 2022 Feb 14, 2023	BUY	$39.45 - $51.77 $1.59 Million - $2.09 Million	40,300 New	40,300 $1.94 Million
Q2 2022 Aug 15, 2022	SELL	$26.03 - $67.04 $471,064 - $1.21 Million	-18,097 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$42.12 - $59.36 $86,472 - $121,866	2,053 Added 12.8%	18,097 $984,000
Q4 2021 Feb 14, 2022	BUY	$36.95 - $62.89 $592,825 - $1.01 Million	16,044 New	16,044 $939,000
Q2 2021 Aug 16, 2021	SELL	$42.4 - $70.11 $722,750 - $1.2 Million	-17,046 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$54.0 - $75.28 $920,484 - $1.28 Million	17,046 New	17,046 $1.05 Million

Others Institutions Holding KROS

# of Institutions

153

Shares Held

26.7M

Call Options Held

47.6K

Put Options Held

34.5K

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.18B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.

Account

Schonfeld Strategic Advisors LLC Keros Therapeutics, Inc. Transaction History